Page last updated: 2024-12-05

bendazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bendazole: also an NSAID; Russian drug; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID12132
CHEMBL ID355063
CHEBI ID134876
SCHEMBL ID309393
MeSH IDM0045512

Synonyms (80)

Synonym
AC-16125
BB 0241942
nsc-631632
nsc631632
2-benzyl-1h-benzimidazole
ENAMINE_004617
bendazole
dibasol
nsc-60020
benzimidazole, 2-benzyl-
621-72-7
tromasedan
1h-benzimidazole, 2-(phenylmethyl)-
nsc60020
dibazol
bendazol
dibazole
2-benzylbenzimidazole
2-benzylbenziminazole
bendazolum [inn-latin]
bendazol [inn:dcf]
einecs 210-703-6
brn 0159495
nsc 60020
bendazolo [dcit]
2-(phenylmethyl)-1h-benzimidazole
D07504
dibazol (tn)
bendazol (inn)
OPREA1_810669
STK298846
2-benzyl-1h-benzoimidazole
OPREA1_667015
MLS001240258
MLS001212883
smr000514120
CHEBI:134876
AKOS000275564
HMS1407B19
CHEMBL355063
A833626
2-benzyl-1h-benzo[d]imidazole
NCGC00245123-01
BBL010591
2-benzyl-1h-1,3-benzodiazole
HMS2234P09
S3589
bdbm50404901
bendazolo
unii-26601thn1d
26601thn1d ,
5-23-08-00498 (beilstein handbook reference)
bendazolum
FT-0632604
HMS3373C18
bendazol [mi]
bendazol [who-dd]
bendazol [inn]
F0037-5472
SCHEMBL309393
AB00277645-07
Q-200678
AF-615/00098050
2-benzyl-1h-benzimidazole #
HY-B2141
CS-8010
DTXSID80211157
Z55692912
mfcd00022680
sr-01000787186
SR-01000787186-3
AC-32030
2-benzylbenzimidazole,tech.
DS-3426
bendazol;2-benzylbenzimidazole
BCP22654
Q4083689
bendazol hydrochloride,(s)
BRD-K60379054-001-07-0
EN300-04389

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The aims of the present study were to investigate the pharmacokinetics of isotonitazene in rats, and relate pharmacokinetic parameters to pharmacodynamic effects."( Plasma pharmacokinetics and pharmacodynamic effects of the 2-benzylbenzimidazole synthetic opioid, isotonitazene, in male rats.
Baumann, MH; Glatfelter, GC; Krotulski, AJ; Logan, BK; Walther, D; Walton, SE, 2023
)
0.91
"In summary, isotonitazene is a potent MOR agonist whose pharmacodynamic effects are related to circulating concentrations of the parent drug."( Plasma pharmacokinetics and pharmacodynamic effects of the 2-benzylbenzimidazole synthetic opioid, isotonitazene, in male rats.
Baumann, MH; Glatfelter, GC; Krotulski, AJ; Logan, BK; Walther, D; Walton, SE, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
" To observe the effects of sibelium in combination with dibazole and offer a basis for the clinical treatment, 136 patients with angioneurotic headache who were admitted to hospital between February and September 2015 were selected and randomly divided into a test group and a control group, 68 in each."( Sibelium in combination with dibazole in the treatment of angioneurotic headache.
Chang, G; Ju, XN; Li, X; Liu, LL; Wang, ZG; Zhang, SJ,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzimidazolesAn organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency39.81070.044717.8581100.0000AID485294
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency50.11870.036619.637650.1187AID2100
gemininHomo sapiens (human)Potency4.46680.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 2B1Rattus norvegicus (Norway rat)IC50 (µMol)91.20117.40007.80008.2000AID38394
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1282093Inhibition of LPS induced NF-kappa-B transcriptional activity in mouse RAW264.7 cells at 30 uM after 20 hrs by SEAP reporter assay2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Exploration of 2-benzylbenzimidazole scaffold as novel inhibitor of NF-κB.
AID24235Partition coefficient (logP)1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Inhibition of rat hepatic microsomal aminopyrine N-demethylase activity by benzimidazole derivatives. Quantitative structure-activity relationships.
AID38394Inhibitory potency to aminopyrine N-demethylase activity (P450) in hepatic microsomes from phenobarbitone-induced rats.1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Inhibition of rat hepatic microsomal aminopyrine N-demethylase activity by benzimidazole derivatives. Quantitative structure-activity relationships.
AID1282094Inhibition of LPS induced NF-kappa-B transcriptional activity in mouse RAW264.7 cells after 20 hrs by SEAP reporter assay2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Exploration of 2-benzylbenzimidazole scaffold as novel inhibitor of NF-κB.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (47)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (44.68)18.7374
1990's5 (10.64)18.2507
2000's4 (8.51)29.6817
2010's8 (17.02)24.3611
2020's9 (19.15)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 49.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index49.76 (24.57)
Research Supply Index4.29 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index76.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (49.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (4.35%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other66 (95.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]